# Avita Medical Inc. (RCEL)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $111M  
**Price:** $3.97 (-3.64%)

> Avita Medical Inc. is a global regenerative medicine company that focuses on harnessing the body's innate regenerative ability to address significant unmet medical needs in the field of burns, chronic wounds, and skin rejuvenation therapies. The company's core product is the RECELL System, an innovative approach designed to enhance the healing of skin ailments and injuries by using a patient's own skin cells. This system stands out for its ability to significantly reduce the need for extensive skin grafting, which is traditionally required in burn treatment, thereby minimizing donor site morbidity and improving patient outcomes.

Avita Medical is particularly influential in the healthcare and biotechnology sectors, providing a crucial solution for patients and medical practitioners dealing with burn treatment and epithelial resurfacing procedures. Its technology holds the potential to revolutionize standard care practices due to its minimally invasive application and efficient healing outcomes. With international recognition, the company plays a vital role in advancing the field of regenerative medicine, offering hope through innovations that enhance quality of life for patients with serious skin injuries and conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $72M | $59M | -$43M | -$49M | $-1.74 |
| 2024 | $64M | $55M | -$57M | -$62M | $-2.39 |
| 2023 | $50M | $42M | -$43M | -$35M | $-1.40 |
| 2022 | $34M | $28M | -$28M | -$27M | $1.07 |
| 2021 | $29M | $23M | -$27M | -$27M | $1.17 |
| 2020 | $14M | $11M | -$43M | -$42M | $2.07 |
| 2019 | $5M | $4M | -$26M | -$25M | $1.56 |
| 2018 | $929,000 | $383,000 | -$14M | -$13M | $1.37 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $56M | $73M | -$17M | $10M | — |
| 2024 | $80M | $75M | $4M | $14M | $42M |
| 2023 | $112M | $62M | $49M | $22M | $40M |
| 2022 | $98M | $13M | $85M | $18M | — |
| 2021 | $126M | $10M | $116M | $111M | — |
| 2020 | $82M | $10M | $72M | $74M | — |
| 2019 | $26M | $5M | $21M | $20M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$31M | $1M | -$32M |
| 2024 | -$49M | $9M | -$58M |
| 2023 | -$38M | $1M | -$39M |
| 2022 | -$19M | $452,000 | -$20M |
| 2021 | -$26M | $894,000 | -$27M |
| 2020 | -$23M | $590,000 | -$23M |
| 2019 | -$19M | $1M | -$20M |
| 2018 | -$13M | $365,000 | -$13M |

Source: [CompaniesByCap](https://companiesbycap.com/company/RCEL)